Prediction-augmented lung cancer screening: a pragmatic VA trial
Official title: Prediction Augmented Screening Initiative
Run by VA Office of Research and Development · NCT06538636 · Data updated 2026-11-12
This trial tests whether using prediction models to identify Veterans who would benefit most from lung cancer screening can be feasibly implemented at the point of care and increase screening uptake.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 50 Years to 80 Years |
| Sex | All |
| Enrollment | 23520 (estimated) |
| Sponsor | VA Office of Research and Development Federal |
| Locations | 4 sites (Bedford, Massachusetts and 3 other locations) |
| Status | Recruiting |
| Started | June 1, 2026 |
| Main results expected | March 5, 2029 |
| Study ends | September 30, 2029 |
| Registry record updated | June 26, 2026 |
| Trial ID | NCT06538636 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Veterans with a primary care relationship at participating VA sites who meet LCS eligibility by USPSTF criteria or have a high predicted benefit for annual LCS.
✕Probably not a fit
Individuals who do not meet eligibility criteria or have a predicted low benefit from annual LCS may not receive added benefit from the intervention.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a large, pragmatic trial conducted within the VA to see if prediction-augmented lung cancer screening can be integrated into routine care. It compares standard USPSTF-based screening criteria with an approach that also uses a life-year gain model to flag high-benefit individuals for LCS. Interventions include clinician-facing tools and population management tools to guide shared decision-making and outreach. The study focuses on reducing disparities in screening uptake, particularly among Black Veterans, by tailoring discussions and recommendations. The trial is led by VA Office of Research and Development with participating VA sites in Bedford, Boston, and Ann Arbor.
Why it matters
Potential benefit: If successful, the approach could make LCS more efficient and equitable, potentially saving lives by increasing screening among those most likely to benefit.
How similar studies have gone: This study builds on prior evidence for LCS benefit and uses prediction-augmented screening as a potentially more efficient approach; prior data on this exact pragmatic implementation are limited, making this relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: Veterans assigned a PCP at a participating site and who meet inclusion criteria at any point during the study timeframe will be enrolled into the trial. There will be two paths to patient inclusion: * meeting USPSTF eligibility criteria for LCS, as currently encoded in the background logic of LCS clinical reminders maintained by the VA National Center for Lung Cancer Screening (i.e., age 50-80 years; smoked 20 pack-years; current smoking or quit \<15 years ago) OR * predicted benefit calculated using LYFS-CTVA model exceeds a stringent high-benefit threshold of life-year gains with annual LCS, as recommended in the 2021 CHEST LCS guidelines Exclusion Criteria: * Veterans who have previously undergone lung cancer screening, are diagnosed with lung cancer, or who do not meet eligibility criteria outlined above
Where it's running
-
Ralph H. Johnson VA Medical Center, Charleston, SC
Charleston, South Carolina, United States Recruiting -
VA Bedford HealthCare System, Bedford, MA
Bedford, Massachusetts, United States Not yet recruiting -
VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA
Boston, Massachusetts, United States Not yet recruiting -
VA Ann Arbor Healthcare System, Ann Arbor, MI
Ann Arbor, Michigan, United States Not yet recruiting
Study contacts
- Principal investigator: Nichole T Tanner, MD MS BS — Ralph H. Johnson VA Medical Center, Charleston, SC
- Study coordinator: Nichole T Tanner, MD MS BS
- Email: Nichole.Tanner@va.gov
- Phone: (843) 789-7341
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Developing and validating a blood test that reads DNA methylation to diagnose lung cancer
This project will test a blood test that looks at DNA changes to see if it can detect lung cancer in people being screened or treated.
-
Counseling methods for quitting smoking
This study is testing whether video counseling can help older smokers quit smoking just as well as traditional in-person counseling.
-
ePRO in advanced lung cancer: emotional distress, brain metastasis, and symptom burden
This study tests how patients with advanced lung cancer—some with brain metastases—report emotional distress and symptoms over time using electronic questionnaires.
-
Urine VOC Test to Detect Lung Cancer in Never Smokers
A urine test that looks for volatile compounds is tested to see if it can help detect lung cancer in adults who have never smoked.
-
SI-B036 safety test in advanced and metastatic solid tumors
This early-phase study checks whether SI-B036 is safe and tolerable in adults with advanced or metastatic solid cancers who have had prior therapy.
-
Guaraná Supplement for Cancer-Related Fatigue in People Undergoing Treatment
This study tests whether taking guaraná capsules helps reduce cancer-related fatigue and improve quality of life in adults with breast, lung, colorectal, or gastric cancer who are actively receiving treatment.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.